Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

• Status: Completed
• Trial end date: 2018-11-06
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether treatment with sitagliptin reduces the frequency and severity of high blood sugar (hyperglycemia) after cardiac surgery and to determine whether treatment with sitagliptin is effective in maintaining blood sugar control in patients with type 2 diabetes (T2D).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Emory University
• Treatments: Insulin; Insulin Aspart; Insulin degludec, insulin aspart drug combination; Insulin Glargine; Insulin Lispro; Insulin, Globin Zinc; Insulin, Long-Acting; Polystyrene sulfonic acid; Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• The ability to provide informed consent

• Ages 18 to 80 years old

• Male or female

• Scheduled to undergo cardiac surgery

• Type 2 Diabetes treated with diet, oral agents,

Exclusion Criteria:

• Severely impaired kidney function (glomeruler filtration rate (GFR ) less than 30 ml/min)

• Clinically significant liver failure

• Imminent risk of death (brain death or cardiac standstill)

• Gastrointestinal obstruction or adynamic ileus

• Expected to require gastrointestinal suction

• Clinically relevant pancreatic or gallbladder disease

• Using oral or injectable corticosteroid

• Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study

• Female subjects are pregnant or breast feeding at time of enrollment into the study